Absci (ABSI) vs Medpace (MEDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Absci (ABSI) has outperformed Medpace (MEDP) over the past year, gaining 113.9% versus a gain of 13.6%. Over five years, MEDP leads with a +223.0% price change compared with -15.9% for ABSI. Medpace is the larger company by market cap ($16.82 billion vs $1.53 billion), about 11.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | MEDP |
|---|---|---|
| Share price | $8.94 | $602.70 |
| Market cap | $1.53B | $16.82B |
| 1-day change | -3.04% | -0.26% |
| YTD return | +156.16% | +7.58% |
| 1-year return | +113.88% | +13.61% |
| 5-year return | -15.90% | +222.99% |
| P/E ratio (TTM) | — | 35.39 |
| Forward P/E | — | 31.20 |
| EPS (TTM) | $-0.79 | $17.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.53B |
| Revenue growth (YoY) | — | +19.97% |
| Net income (latest FY) | — | $451.12M |
| Operating margin | — | 21.14% |
| Net margin | — | 17.83% |
| 52-week high | $12.06 | $677.90 |
| 52-week low | $2.24 | $373.00 |
| Distance from 52-week high | -25.84% | -11.09% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +61.07% | -1.80% |
| Average volume | 3.45M | 272.38K |
| Shares outstanding | 171.61M | 27.91M |
| Employees | 140 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medpace is about 11.0 times larger than Absci by market value ($16.82B vs $1.53B).
- ABSI has outperformed MEDP by 100.3 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About Medpace
MEDP stock →Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 6,500 employees
ABSI vs MEDP FAQ
Which is bigger, Absci or Medpace?
Medpace (MEDP) is larger, with a market capitalization of $16.82B compared with $1.53B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or MEDP?
ABSI returned +113.88% over the past 12 months, compared with +13.61% for MEDP (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Medpace in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.